SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001438533-22-000049
Filing Date
2022-10-27
Accepted
2022-10-27 16:17:16
Documents
14
Period of Report
2022-10-27
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K tvtx-20221027.htm   iXBRL 8-K 42901
2 EX-99.1 a2022q3_8-kxex991.htm EX-99.1 193190
6 GRAPHIC imagea.jpg GRAPHIC 12958
  Complete submission text file 0001438533-22-000049.txt   413560

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT tvtx-20221027.xsd EX-101.SCH 1899
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT tvtx-20221027_lab.xml EX-101.LAB 25154
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT tvtx-20221027_pre.xml EX-101.PRE 13044
8 EXTRACTED XBRL INSTANCE DOCUMENT tvtx-20221027_htm.xml XML 11268
Mailing Address 3611 VALLEY CENTRE DR SUITE 300 SAN DIEGO CA 92130
Business Address 3611 VALLEY CENTRE DR SUITE 300 SAN DIEGO CA 92130 888-969-7879
Travere Therapeutics, Inc. (Filer) CIK: 0001438533 (see all company filings)

IRS No.: 262383102 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36257 | Film No.: 221337527
SIC: 2834 Pharmaceutical Preparations